iv fluid monitoring devices market

Contakt World Provides Company Update as it Continues to Expand its Portfolio of SaaS Solutions and Commercial Presence in the US Market

Contakt World is well-positioned to continue to take a leading role as a provider of SaaS solutions designed to meet Federal Vaccine Mandates imposed by the United States

  • A vaccine mandate was recently enacted in the United States for all Federal employees
  • The private sector is following suit, creating demand for Contakt World's portfolio
  • Health Check and Portum's app offers the public and private sector a unique, integrated solution

Contakt World Technologies Corp. (CSE: HELP) (OTC Pink: TLOOF) (FSE: B2I0) (the "Company", "Contakt" or "Contakt World"), a SaaS company committed to improving health equity and access to healthcare while solving sector specific business challenges such as symptom screening and vaccine passports, is pleased to provide a summary of the Company's recent achievements, current operations, and strategic initiatives.

Contakt World has ambitious plans to advance its business following its acquisition of Stratum Health Solutions LLC ("Stratum"), the operator of HealthCheck by Stratum™ ("HealthCheck") and execution of a reseller's agreement with Portum System LLC ("Portum") for the US, Canada, and Brazil markets. A review of the Company's recent achievements and current business is as follows:

  • On August 12, 2021, Contakt acquired Stratum (Health Check) a secure, cloud-based platform that allows organizations of all sizes to track and evaluate employee and student health and COVID-19 related symptoms in real-time through its proprietary app (the "App"). Contakt continues to expand its presence in the marketplace with Health Check with the hiring of 10 commission-based sales people over the last few months. The Company's team is fully trained and has acquired 20+ significant new customers over the last few months with over 25 new commercial opportunities in the pipeline. Contakt has engaged a software development company, ModalGR, located in Brazil, to add new features to the App, including vaccine passport and COVID-19 test tracking. Contakt expects to launch the new version of the App in December of this year.
  • On October 14, 2021, Contakt expanded its commercial portfolio through a partnership agreement with Portum through which the Company will offer Portum's app and software to commercial and government customers to help implement vaccine mandates in public and private settings. The Company's sales team has been fully trained and has started to promote this SaaS product across the USA. This solution will allow the Company to immediately offer a vaccine passport and COVID-19 test tracking solution to its existing and new customers. With several states, such as New York and California, enforcing vaccine mandates, Contakt is focusing on these territories to rapidly gain market share.
  • Contakt recently hired Alexandre Kochmann, a seasoned executive located in Brazil, to oversee the commercialization and product development of the Health Check and Portum solutions. Alexandre brings 20+ of experience managing large commercial sales forces at large corporations such as Dupont, GLOBALPACK and EMPAX.
  • With a focus on the private sector, Contakt has dramatically reduced its burn rate. While the Company sees long-term opportunities in the public health markets, it is focusing on continuing to build the Health Check business and partnership with Portum.
  • Contakt is also eyeing opportunities in the Brazilian market and anticipates having a Portuguese version of the App ready in the first half of 2022, which will allow it to offer a robust solution to one of the largest economies in the world.

"By leveraging the Company's expanding team of independent sales representatives and continuing the development of our Health Check platform to meet the needs of vaccine passport and COVID-19 test tracking mandates, we believe our team will serve as a strong platform to develop and acquire additional SaaS solutions, ultimately strengthening our product portfolio," stated Zayn Kalyan, Chief Executive Officer of Contakt World.

Corporate Update Webinar
Contakt will be hosting a corporate update webinar for shareholders at 12pm PST on Friday November 19, 2021. Please click here to register.

Other Recent Related News from Contakt World:

Contakt World Launches Sales Representative Program to Continue to Grow Revenue for Its Cash Flow Positive HealthCheck Screening Tool and Vaccine Passport Solution

Contakt World to Offer Vaccine Passport and Verification Platform to Employers, Events and Organizations, Including Customers of Recently Acquired HealthCheck App

Contakt World Announces Acquisition of HealthCheck, a SaaS Health Screening App for Students, Customers, Employees, and Visitors

To Learn More:
If you are an organization seeking daily health screening and vaccine passports, vaccine wallets, or vaccine credentials, schedule a demo by visiting https://www.stratumhealth.io/. Our team will work with your organization to define the product that better suits your needs.

About Contakt World
Contakt World's mission is to develop or acquire and deliver software (SaaS) that improves access to, efficiencies within, and quality of healthcare in all its forms. Contakt World envisions a world where everyone can achieve their full health potential, and no one is disadvantaged from achieving this potential because of social position or other circumstances. Contakt World's portfolio presently includes HealthCheck by Stratum which is used in over 1,000 locations, and Portum Pass https://contakt.world/portum/.

Sign up for investor updates from Contakt World including updates in the field of vaccine passports by visiting https://contakt.world/help.

Contakt World Contact
Zayn Kalyan
Interim CEO and Director
Direct: 778-938-3367

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Forward-Looking Statements Disclaimer

This press release contains "forward-looking information" within the meaning of applicable securities laws ("forward-looking statements"). Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "projects", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements, including statements respecting: the Company's plans to advance its business following its acquisition of Stratum and partnership agreement with Portum; Contakt's plan to launch a new version of the App in December 2021; the Portum arrangement's potential to allow the Company to immediately offer a vaccine passport and COVID-19 test tracking solution to its existing and new customers; the Company's focus on continuing to build the Health Check business and partnership with Portum; expected timing and functionality of a Portuguese version of the App; the Company's belief that its team will serve as a strong platform to develop and acquire additional SaaS solutions, ultimately strengthening the Company's product portfolio. Although forward-looking statements contained in this press release are based upon what management of Contakt World believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements may also be affected by risks and uncertainties in the business of Contakt World, including those described in the Company's public filings available on www.SEDAR.com. Contakt World undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103682

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×